Across TCGA pan-cancer cohorts, DNAJC18 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DNAJC18 data layer compared with 21 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher DNAJC18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJC18 expression acts as an unfavorable survival marker.
GBM are the cancer types where DNAJC18 mass-spec protein most reproducibly stratifies survival.